Life Sciences AISeedWorkflow signalℹ124Serinus Biosciences
Serinus Biosciences uses a knowledge-primed AI engine to design cancer combination therapies by mapping how tumor cells evolve treatment resistance and identifying molecules that override resistance escape routes.
Why people are saving it
Relevant for oncology drug discovery teams tracking AI-driven approaches to tumor resistance mechanisms and combination therapy design.
What they're building
Serinus Biosciences is building a knowledge-primed AI engine that maps how tumor cells evolve resistance to treatment and identifies molecules capable of overriding those escape routes.
Founders
Maxwell Sherman
Co-founder
Adam Yaari
Co-founder
Foundation model usage
Serinus Biosciences applies models to biological data where retrieval, structure, and multimodal reasoning matter.
NYC footprint
Serinus Biosciences is part of the New York City AI startup scene, with a profile focused on its market category, stage, and product signal.
Funding
Latest funding: Seed.
Platform / OpenAI fit
Strong fit for multimodal reasoning, biological data retrieval, molecule and protein analysis, structured extraction, and research copilots.
Notes
Serinus Biosciences is tagged workflow signal based on buyer clarity, repeat workflow signal, public activity, and fit with the AI Atlas map.
Related NYC startups
Protein interaction maps for drug discovery
Proxima Bio, formerly VantAI, is an AI-native platform for proximity-based drug discovery, mapping protein-protein interactions to design medicines that reshape protein networks rather than inhibit single targets.
Life Sciences AIWorkflow signalℹ83viewsRecent Activity
Protein interaction maps for drug discovery
Output Biosciences is building Large Biological Models, generative AI architectures designed to handle the long, nonlinear, fragmented data of biological systems across molecules, cells, and organisms.
Life Sciences AIWorkflow signalℹ29viewsRecent Activity